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Background. Randomized controlled trials (RCT) gen-
eralizability may be limited due to strict patient
selection.
Objective. In a real-world heart failure (HF) popula-
tion, we assessed eligibility for sacubitril/valsartan
based on PARADIGM-HF (sacubitril/valsartan
effective)/PARAGON-HF [sacubitril/valsartan
effective in mildly reduced ejection fraction (EF)].
Methods. Outpatients from the Swedish HF Registry
(SwedeHF)wereanalysed. InSwedeHF,EF is recorded
as <30, 30–39, 40–49 and ≥50%. In PARAGON-HF,
sacubitril/valsartan was effective with EF ≤ 57% (i.e.
median). We defined reduced EF/PARADIGM-HF as
EF < 40%, mildly reduced EF/PARAGON-HF ≤ me-
dian as EF 40–49%, and normal EF/PARAGON-
HF > median as EF ≥ 50%. We assessed 2 scenarios:
(i) criteria likely to influence treatment decisions
(pragmatic scenario); (ii) all criteria (literal scenario).
Results. Of 37 790 outpatients, 57% had EF < 40%,
24% EF 40–49% and 19% EF ≥ 50%. In the prag-
matic scenario, 63% were eligible in EF < 50%
(67% for EF < 40% and 52% for 40–49%) and 52%
in EF ≥ 40% (52% for EF ≥ 50%). For the literal
scenario, 32% were eligible in EF < 50% (38% of
EF < 40%, 20% of EF 40–49%) and 22% in
EF ≥ 40% (25% for EF ≥ 50%). Eligible vs. noneli-
gible patients had more severe HF, more comor-
bidities and overall worse outcomes.
Conclusion. In a real-world HF outpatient cohort, 81%
of patients had EF < 50%, with 63% eligible for
sacubitril/valsartan based on pragmatic criteria
and 32% eligible based on literal trial criteria.
Similar eligibility was observed for EF 40–49% and
≥50%, suggesting that our estimates for EF < 50%
may be reproduced whether or not a higher cut-off
for EF is considered.
Keywords: eligibility, PARADIGM-HF, PARAGON-HF,
sacubitril/valsartan, trial.
Introduction
The prognosis in patients with heart failure (HF)
remains poor regardless of ejection fraction (EF)
[1]. An increasing number of pharmacological
treatments have been shown to benefit patients
with HF with reduced EF (HFrEF; EF < 40%) [2]. In
contrast, randomized controlled trials (RCTs) in
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patients with HF with preserved EF (HFpEF;
EF ≥ 50%) were not successful to date. Thus,
treatment recommendations in HFpEF are limited
to risk factors modification, comorbidities and
symptoms management [2]. Notably, patients with
HF with mid-range EF (HFmrEF; EF = 40–49%)
have mildly reduced EF but were excluded from
HFrEF trials [1]. Post hoc analyses of RCTs suggest
that HFmrEF may benefit from established HFrEF
treatments [3].
In the PARADIGM-HF trial, sacubitril/valsartan
improved survival/morbidity in HFrEF compared
to enalapril [4]. Recently, the PARAGON-HF trial
tested sacubitril/valsartan vs. valsartan in HF
with EF ≥ 45% [5]. Lower, although not statisti-
cally significant, rates of cardiovascular death/
total HF hospitalizations were observed in
patients treated with sacubitril/valsartan [5].
Notably, a prespecified subgroup analysis sug-
gested a potential efficacy in patients with
EF ≤ median, which was 57%. This suggests that
the benefit of sacubitril/valsartan observed in
PARADIGM-HF could extend at least to the mildly
reduced EF [5], and thus may even challenge the
current definition of HFrEF to include also the
mid-range or mildly reduced EF.
RCTs apply inclusion/exclusion criteria to ensure
HF diagnosis, enrich for modifiable events and
minimize nonmodifiable competing risk [6, 7].
Therefore, generalizability of RCTs is often ques-
tioned and may limit implementation [8]. We
assessed the proportion and characteristics of HF
patients with reduced/mildly reduced EF (<50%)
and with mildly reduced/preserved EF (EF ≥ 40%)
who would be eligible for sacubitril/valsartan




The Swedish Heart Failure Registry (SwedeHF;
www.SwedeHF.se) has been previously described
[9]. Briefly, patients with clinician-judged HF have
been included in the registry since 11 May 2000.
Approximately 80 variables are recorded at dis-
charge from the hospital or after an outpatient
clinic visit and entered into a web-based case
report form and database managed by Uppsala
Clinical Research Center (www.ucr.se). Echocar-
diographic parameters other than EF are not
collected.
The Swedish Board of Health andWelfare (www.soc
ialstyrelsen.se) administers the National Patient
Registry, which provided additional data on base-
line comorbidities and the outcome HF hospital-
ization, and the Cause of Death registry which
provided the underlying rather than the immediate
cause of death, defined by ICD-10 codes. ICD-10
coding in Sweden has been validated, with a
positive predictive value ranging between 85%
and 95% for most diagnoses. From Statistics
Sweden (www.scb.se) we obtained socioeconomic
characteristics. All Swedish citizens have unique
personal identification numbers that allow linking
of disease-specific health registries and govern-
mental health and statistical registries. The Swe-
deHF registry and the present analysis with linking
of the above registries were approved by an ethics
committee. Individual patient consent was not
required, but patients were informed of entry into
national registries and allowed to opt out.
Eligibility for sacubitril/valsartan
In SwedeHF, EF is categorized as <30%, 30–39%,
40–49% and ≥50%. In PARAGON-HF, sacubitril/
valsartan was effective with EF ≤ median (57%) [5].
Thus, in this analysis, HFrEF/PARADIGM-HF was
defined as EF < 40%, mildly reduced EF/PARA-
GON-HF ≤ median was conservatively defined as
EF 40–49% (since we could not define it as ≤57%)
and preserved EF/PARAGON-HF > median was
defined as EF ≥ 50%.
Two cohorts were analysed. We were primarily
interested in assessing eligibility in patients where
sacubitril/valsartan was effective and may be
used. Therefore cohort 1 included reduced + mildly
reduced EF (EF < 50%) and we used selection
criteria from PARADIGM-HF for EF < 40% and
from PARAGON-HF for EF 40-49%. Even though
clinical trial data do not conclusively support the
use of sacubitril/valsartan in strictly preserved EF,
we nevertheless wished to also assess eligibility in
a PARAGON-HF like cohort. Therefore, cohort 2
had mildly reduced + preserved EF (EF ≥ 40%) and
we used selection criteria from PARAGON-HF.
These cohorts were thus not mutually exclusive
(i.e. EF 40–50% was included in both).
SwedeHF patients were considered potentially eli-
gible, and thus included in the denominator for the
calculation, if they were outpatients and had
EF < 50% (cohort 1) or EF ≥ 40% (cohort 2). If the
same patient had multiple registrations, the last
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one without missing data for location (i.e. inpatient
vs. outpatient) and EF was considered.
We considered 2 potential scenarios, the pragmatic
and the literal. In the pragmatic scenario eligibility
was defined according to selected PARADIGM-HF/
PARAGON-HF inclusion/exclusion criteria which
may be more likely to influence the likelihood of
receiving sacubitril/valsartan in clinical practice
[age, New York Heart Association (NYHA) II-IV, N-
terminal pro-B-type natriuretic peptide (NT-
proBNP) criteria, history of angioedema, pul-
monary arterial hypertension (PARAGON-HF only),
systolic blood pressure (SBP) < 110 mmHg for
PARAGON-HF and <100 mmHg for PARADIGM-
HF, pericardial constriction/hypertrophic/
infiltrative cardiomyopathy for PARAGON-HF only,
psychiatric illness for PARAGON-HF only and esti-
mated glomerular filtration rate (eGFR)
<30 mL min1/1.73 m2]. In the literal scenario
eligibility was defined according to all the trials’
inclusion/exclusion criteria which could be
assessed in our dataset. Eligibility was also
assessed separately in females vs. males. The
original definitions of the trials’ entry criteria [10,
11], as well as the corresponding definitions in
SwedeHF are reported Table S1 and in Table 1,
respectively.
In order to handle missing data for variables
involved in the definition of the inclusion/exclu-
sion criteria, for each scenario we performed 3
Table 1. Eligibility for sacubitril/valsartan based on PARADIGM-HF/PARAGON-HF selection criteria in the main study














2 Age ≥ 50 in PARAGON-HF/≥18 in PARADIGM-HF 98.4% 95.4%
3 EF 100% 100%
4 Diuretic treatment at discharge for PARAGON-HF/ACEi or ARB equivalent to enalapril
10 mg day1 and BBl at discharge for PARADIGM-HF
69.8% 69.7%
5 NYHA II-IV 87.9% 83.7%




7 NT-proBNP criteria 84.8% 80.4%
Eligible (literal scenario) only inclusion criteria 54.4% 54.7%
Eligible (pragmatic scenario) only inclusion criteria 75.9% 68.6%
Exclusion criteria
1 Any prior echocardiographic measurement of EF < 40% for PARAGON-HF 96.0% 88.6%
2 Acute coronary syndrome/major cardiovascular interventions within 3 months prior to
the index date
89.4% 91.9%






4 Current acute decompensated HF 100% 100%
5 Patients with both ACEi and ARB at discharge 97.8% 98.6%




7 Known history of angioedema 100% 100%
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8 Pulmonary arterial hypertension (included in the pragmatic scenario only for
PARAGON-HF)
99.7% 99.4%
8 BMI > 40 kg m2 99.2% 96.7%
8 Haemoglobin < 10 g dL1 99.5% 97.9%
9 SBP ≥ 180 mmHg (PARAGON-HF) 99.5% 98.1%
9 SBP > 150 mmHg and <180 mmHg at baseline, unless the patient is receiving 3 or more
antihypertensive drugs (assuming all receive CCBs)
99.8% 99.1%
9 SBP < 110 mmHg (PARAGON-HF)/<100 mmHg (PARADIGM-HF) 89.8% 86.6%




11 History of dilated cardiomyopathy 97.4% 92.7%




13 Pericardial constriction/hypertrophic or infiltrative cardiomyopathy (PARAGON-
HF)
98.7% 95.0%
14 Clinically significant congenital heart disease 99.6% 98.7%




16 Stroke or TIA within 3 months prior to index date 98.7% 99.1%




18 AF and HR > 110 99.7% 99.0%
19 CRT 94.2% 98.2%
20 Previous major transplant 99.8% 99.5%
21 Trial scenario – Mental disorders (PARAGON-HF) 99.2% 97.3%
21 Pragmatic scenario – Mental disorders (PARAGON-HF) 99.9% 99.5%
22 Pancreatic disease within 5 years prior to index date (PARAGON-HF)/Liver disease within
1 year or Crohn within 1 year or Duodenal or gastric ulcers within 3 months
(PARADIGM-HF)
98.8% 99.9%
23 History of liver disease (PARAGON-HF) 99.7% 98.8%
24 eGFR < 30 mL min1/1.73 m2 94.7% 94.1%




26 Potassium > 5.2 mmol L1 98.3% 98.4%








29 Drug or alcohol abuse within the past 12 months 99.9% 99.5%
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different analyses. As main analysis, missing data
were imputed. As consistency analysis, (i) patients
with missing data for a specific criterion were
considered as eligible (missing as eligible); (ii)
patients with missing data for any of the inclu-
sion/exclusion criteria were excluded from the
analysis (i.e. from both numerator and denomina-
tor complete case analysis).
Statistical analyses
The eligibility estimates were reported as numbers
and percentages of the remaining cohort after
applying the respective inclusion/exclusion crite-
ria. Baseline characteristics were reported as fre-
quencies (percentages) for categorical variables
and as medians [interquartile range (IQR)] for
continuous variables and compared in eligible vs.
noneligible patients by chi-square and Mann–
Whitney tests, respectively. In the main analysis,
missing data were imputed once (since one single
value was needed for eligibility calculation)(R-
package mice) using the variables reported in the
legend of Table 1. Patients with missing doses of
angiotensin converting enzyme inhibitors (ACEi)/
angiotensin receptor blocker (ARB) or patients with
ACEi/ARB imputed as ‘on treatment’ in EF < 40%
analyses (i.e. PARADIGM-HF criteria) were consid-
ered as receiving a dose equivalent to enalapril
10 mg day1.
Incidence rates (per 100 patient-years) for all-
cause, cardiovascular and noncardiovascular mor-
tality, HF hospitalization and the composite of
cardiovascular mortality or HF hospitalization were
compared in eligible vs. noneligible patients by
exact Poisson test.
A P-value < 0.05 (two-tailed) was considered sta-
tistically significant. All statistical analyses were
performed in R software version 3.6.1. The R code
for all analysis is available on https://github.com/
KIHeartFailure/eligibilitySacubitrilValsarta
nSwedeHF.





31 Malignancy within the past 5 years prior to index (PARAGON-HF) 95.5% 84.8%








Eligible (literal scenario) only exclusion criteria 58.8% 41.3%
Eligible (pragmatic scenario) only exclusion criteria 84.1% 77.0%
Eligible (literal scenario) 32.2% 22.1%
Eligible (pragmatic scenario) 62.7% 51.7%
Eligibility estimates reported as numbers and percentages and representing the remaining cohort after applying the
respective inclusion/exclusion criteria. The criteria were not ordered and mutually exclusive.
Variables included in the pragmatic scenario in bold.
Variables included in the imputation models were: sex, age, follow-up referral to specialty/primary care, follow-up referral
to heart failure nurse-led clinic, year of registration, marital status, educational level, income, heart failure duration, New
York heart association class, ECG, systolic blood pressure, heart rate, estimate glomerular filtration rate, haemoglobin, N-
terminal pro-B-type natriuretic peptide, potassium, angiotensin converting enzyme inhibitors/angiotensin receptor
blockers, mineralocorticoid receptor antagonist, diuretic, nitrate, antiplatelet, anticoagulant, statin, beta-blocker, digoxin,
smoking, cardiac resynchronization therapy/implantable cardioverter defibrillator, body mass index category, hyperten-
sion, diabetes, ischaemic heart disease, myocardial infarction, peripheral vascular disease, stroke/transient ischaemic
attack, valvular disease, dilated cardiomyopathy, chronic obstructive pulmonary disease, malignancies (within 5 years),
alcohol/drug abuse (within 1 year), mental disease (within 1 year).
ACEi, Angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass
index; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart
failure with preserved ejection fraction; HR, heart rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New
York Heart Association; SBP, systolic blood pressure; TIA, Transient Ischaemic Attack.
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Results
Between 11 May 2000 and 31 December 2016,
130 420 registrations were recorded in SwedeHF.
Of these, 114 737 registrations had entries for EF,
with 59 668 registered in outpatient setting. After
the exclusion of multiple entries per patient,
37 790 unique registrations/patients were consid-
ered for our analyses.
Cohort 1 consisted of 30 618 (81%) patients with
mildly reduced/reduced (i.e. EF < 50%), including
21 484 (57%) with reduced EF (EF < 40%) + 9134
(24%) with mildly reduced EF (EF = 40–49%).
Cohort 2 consisted of 16 306 (43%) patients with
mildly reduced + preserved EF (i.e. EF ≥ 40%),
including 9134 (24%) with mildly reduced (EF 40–
49%) + 7172 (19%) with preserved EF (EF ≥ 50%).
Patients with mildly reduced EF were thus
included in both study groups.
Patient characteristics according to EF are
reported in Table S2.
Eligibility for sacubitril/valsartan in cohort 1, that is, patients with
reduced + mildly reduced EF (EF < 50%)
Of 30 618 patients with EF < 50% screened for
eligibility, in the pragmatic scenario, 76% met the
inclusion criteria (79% for EF < 40%/PARADIGM-
HF and 68% for EF = 40–49%/PARAGON-HF),
whereas 84% (87% and 78%, respectively) were
eligible after applying only the exclusion, and 63%
(67% and 52%, respectively) were eligible based on
both inclusion and exclusion criteria. Overall eligi-
bility was 64% in females vs. 62% in males. Major
unmet inclusion criteria were (i) elevated NT-
proBNP levels and (ii) NYHA class II-IV. Major
exclusion criteria limiting eligibility were (i)
hypotension and (ii) renal dysfunction (Table 1;
Fig. 1; Table S3).
In the literal scenario, 54% of the population met
inclusion criteria (56% for EF < 40%/PARADIGM-
HF and 52% for EF = 40–49%/PARAGON-HF
patients), whereas 59% were eligible after applying
only the exclusion criteria (67% and 40%, respec-
tively), with 32% (38% and 20%, respectively), 33%
in females vs. 32% in males, meeting both inclu-
sion and exclusion criteria. Major unmet inclusion
criteria, which were not considered in the prag-
matic scenario, were (i) angiotensin converting
enzyme inhibitor (ACEi) or angiotensin receptor
blocker (ARB) dose equivalent to enalapril 10mg
daily and concomitant use of a beta-blocker, and
(ii) diuretic use. Major exclusion criterion, beyond
those considered in the pragmatic scenario, was
acute coronary syndrome (ACS) or major cardio-
vascular surgery within 3 months.
Eligibility for sacubitril/valsartan based on PARAGON-HF in cohort 2,
that is, patients with mildly reduced + preserved EF (EF ≥ 40%)
Of 16 306 patients with EF ≥ 40%, in the prag-
matic scenario 69% met inclusion criteria and 77%
were eligible after applying exclusion criteria,
leading to an overall eligibility of 52%; 55% in
females and 49% in males. Consistently with the
findings from cohort 1, major unmet inclusion
criteria were (i) elevated NT-proBNP and (ii) NYHA
class II–IV, whereas major exclusion criteria limit-
ing eligibility were (i) hypotension and (ii) renal
dysfunction (Table 1; Table S3).
In the literal scenario, 55% fulfilled the inclusion
criteria, whereas 41% were eligible after consider-
ing only exclusions, leading to an overall eligibility
of 22%. Overall eligibility was 26% in females vs.
19% in males. The major unmet inclusion criterion,
which was not considered in the pragmatic sce-
nario, was diuretic use. Major exclusion criteria
limiting eligibility, beyond those considered in the
pragmatic scenario, were (i) malignancies within
the last 5 years, (ii) any prior EF < 40% measure-
ment and (iii) ACS or major cardiovascular surgery
within 3 months.
In the pragmatic scenario eligibility was 52% in
both EF = 40–49% and EF ≥ 50% whereas it was
20% and 25%, respectively, in the literal scenario.
Consistency analysis
For all the EF groups and scenarios, eligibility was
similar when, rather than imputing missing data,
we performed complete cases analyses (i.e.
patients with and without missing data were not
substantially different with regards to eligibility),
and as expected, slightly higher when we consid-
ered a missing entry as eligible (Table S4).
Patient characteristics and outcomes in eligible vs. noneligible
populations
In the pragmatic scenario (Table 2), regardless of
EF, eligible vs. noneligible patients were older,
more likely female, less likely to be referred to
specialty care, had more severe HF (e.g. more
Eligibility for sacubitril/valsartan across EF spectrum / G. Savarese et al.
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Fig. 1 Eligibility for sacubitril/valsartan in heart failure with mildly reduced/reduced ejection fraction (EF < 50%) based
on PARADIGM-HF/PARAGON-HF selection criteria in the main study population (missing data imputed). Abbreviations as in
Table 1.
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previous HF hospitalizations, higher NYHA class
and NT-proBNP levels) and comorbidities (e.g.
more patients had eGFR < 60 vs. ≥60 mL min1/
1.73 m2, atrial fibrillation, anaemia, hypertension,
diabetes, chronic obstructive pulmonary disease,
history of cancer). Regardless of EF, use of diuret-
ics, nitrates and digoxin was higher but use of HF
devices lower in eligible vs. noneligible patients.
In HFrEF, eligible patients were more likely to
receive ACEi/ARB, beta-blockers and mineralocor-
ticoid receptor antagonists. Ischaemic heart dis-
ease was more prevalent in eligible vs. noneligible
patients in HFpEF and HFmrEF, with no differ-
ences in HFrEF. There were few differences in
patient characteristics according to eligibility in the
literal vs. pragmatic scenario which reflected the
stricter exclusion criteria applied (Table S5).
Event rates for all the outcomes in eligible vs.
noneligible patients are reported in Fig. 2 and
Table S6 and were higher in eligible patients
regardless of EF in the pragmatic scenario. Eligible
patients had higher event rates for both cardiovas-
cular, noncardiovascular and all-cause mortality.
Similar results were reported in the literal scenario
except for slightly lower mortality rates in eligible
vs. ineligible patients with EF < 50% or EF < 40%,
and lower HF hospitalization risk in eligible vs.
noneligible in EF < 40%.
Discussion
In a large and contemporary real-world cohort with
HF across the EF spectrum, in a pragmatic sce-
nario eligibility for sacubitril/valsartan was 63%
and 52% in EF < 50% and EF ≥ 40%, respectively,
whereas the corresponding estimates were 28%
and 19% when all the trials inclusion/exclusion
criteria were considered (i.e. literal scenario).
Regardless of EF, in the pragmatic scenario,
patients were more likely ineligible by not meeting
inclusion criteria, mainly due to an insufficiently
severe HF status. In the literal scenario, in
EF < 50% inclusion and exclusion criteria similarly
impacted eligibility, whereas in EF ≥ 40% patients
were more likely excluded due to meeting exclusion
criteria, mainly related to comorbidities, which is
consistent with the increasing comorbidity burden
with higher EF.
In PARAGON-HF sacubitril/valsartan improved
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Fig. 2 Event rates in eligible vs. noneligible patients. *P-value < 0.05. Event rates reported as *100 patient-years. CV,
cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved
ejection fraction.
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therefore, its use might possibly be considered in
the lower range of HFpEF and for HFmrEF [12]. In
our analysis, we could not evaluate eligibility based
on the EF = 57% cut-off since EF is collected as a
categorical variable in SwedeHF. However, this
specific cut-off is unlikely to be applied by any
stakeholder and even less in clinical practice. Also,
we observed overall same eligibility estimates in
EF = 40–49% and EF ≥ 50% (52% in both EF
groups in the pragmatic scenario and 17% vs.
19%, respectively, in the literal scenario), suggest-
ing similar eligibility whether a higher EF cut-off is
considered or not.
Major selection criteria driving eligibility
Ineligibility due to inclusion criteria
Ongoing treatment with ACEi/ARB block-
ers. Amongst literal inclusion criteria, nonuse of
beta-blockers or ACEi/ARB equivalent to enalapril
10 mg day1 in EF < 50% and nonuse of diuretics
at baseline in EF ≥ 40% led to the noneligibility of
30% of our population. In HFrEF, whereas optimal
use of ACEi/ARB is still a requirement for initiating
sacubitril/valsartan in some of the current guide-
lines (e.g. European) [2], this is not considered in
the regulatory labelling. Additionally, PIONEER-HF
and TRANSITION suggest that sacubitril/valsartan
is effective and safe also in ACEi/ARB-na€ıve
patients [13, 14]. Based on all these considera-
tions, we did not consider previous ACEi/ARB use/
dose as a limiting factor for sacubitril/valsartan
initiation and thus was not included for our
pragmatic scenario.
Ongoing treatment with diuretics. PARAGON-HF
included patients with symptoms of HF requiring
treatment with diuretics for at least 30 days
prior to the screening visit. In our population we
could not assess use of diuretics prior to the
index visit but we could evaluate use of diuretics
at baseline. Based on the discrepancy between
our and PARAGON-HF definition, we did not
consider use of diuretics at baseline as part of
the pragmatic scenario definition. However, it is
likely that most patients not fulfilling this inclu-
sion criterion did also not meet other important
inclusion criteria which were instead considered
in our pragmatic scenario, that is, were not
included due to low NT-proBNP levels or NYHA
class. The gap between eligibility estimates at
the pragmatic vs. literal scenario was impacted
more by the number of patients meeting the
exclusion criteria rather than not meeting the
inclusion criteria.
Ineligibility due to exclusion criteria
The number of patients ineligible due to the exclu-
sion criteria was higher with increasing EF, which
is consistent with the higher burden of comorbidi-
ties in HFpEF vs. HFmrEF vs. HFrEF.
ACS intervention within 3 months. The exclusion
of patients with history of ACS/major cardiovas-
cular interventions within 3 months prior to the
index event explained the exclusion of 15–20% of
the population across the EF spectrum. However,
initiation of sacubitril/valsartan might be simply
delayed after an acute ischaemic event or cardio-
vascular intervention and thus this exclusion cri-
terion was not considered as likely to influence
eligibility in real-world practice.
History of cancer. History of cancer within 5 years
prior to the enrolment was an exclusion criterion
which was met in 20% of our population with
EF ≥ 40%, highlighting the considerable preva-
lence of cancer in HF with mid-range/preserved
EF [15]. However, this trial criterion is meant to
reduce competing risk. There is no reason to
believe patients with cancer should derive any less
symptom relief or in most cases, prognostic benefit
and thus was not considered in the pragmatic
scenario.
Low NYHA class, low eGFR, low NT-proBNP or
hypotension. There were no major differences in
the proportion of patients meeting the individual
inclusion/exclusion criteria considered in the
pragmatic scenario in EF < 50% vs. EF ≥ 40%. In
our cohort, around 15-20% of patients were not
included due to asymptomatic HF (NYHA class I) or
low NT-proBNP levels. Severe kidney disease and
hypotension limitedly impacted on eligibility esti-
mates regardless of EF, with 6% of our population
excluded for eGFR < 30 mL min1/1.73 m2 and
87/89% for SBP < 100 mmHg according to PARA-
DIGM-HF/110 mmHg according to PARAGON-HF,
respectively.
These estimates were similar to those reported in
the ESC-EORP-HFA HF-LT registry outpatient
cohort based on PARADIGM-HF selection criteria
[16]. Conversely, in a recent study from the GTWG-
HF registry assessing eligibility for sacubitril/val-
sartan based on PARAGON-HF selection criteria,
14% of patients with EF > 40% were excluded for
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eGFR < 30 mL min1/1.73 m2 and 29% for
SBP < 100 mmHg [17]. Higher estimates in
GTWG-HF vs. SwedeHF population might be
explained by the different characteristics of the
populations, with our study considering only out-
patients and GTWG-HF enrolling only hospitalized
patients (which, incidentally, were not eligible for
PARAGON-HF). Differences in risk profile might
also explain the differences in the overall eligibility
for sacubitril/valsartan observed in these two
cohorts, with 19% eligible according to literal
PARAGON-HF selection criteria in SwedeHF vs.
10% in GTWG-HF [17].
Patient characteristics and outcomes according to eligibility status
Regardless of EF, patient characteristics and out-
comes amongst eligible patients were linked to
more severe HF and overall heavier burden of
comorbidities. This was surprising since random-
ized trials exclude patients with multiple comor-
bidities, which is suggested to limit generalizability
to real-world care. Similar patterns were shown in
a previous SwedeHF analysis, assessing eligibility
in HFrEF based on PARADIGM-HF selection crite-
ria [18]. These findings may be explained by
PARADIGM-HF/PARAGON-HF inclusion criteria
being adequately defined to identify a high-risk
HF outpatient population and, at the same time, by
trial exclusion criteria only leading to the exclusion
of patients with very specific characteristics which
were not linked with multiple comorbidities and
more severe HF. This hypothesis might be sup-
ported by the fact that although exclusion criteria
were many and thus impacted overall eligibility,
most of them individually contributed with the
exclusion of a limited proportion of patients. Con-
versely, in the GTWG-HF PARAGON-HF analysis,
eligible patients had generally lower rates of
comorbid diseases and overall lower 1-year mor-
tality compared to those who were noneligible [17].
Applying the selection criteria of PARAGON-HF,
which has been designed to enrol chronic HF
patients, to a very high-risk population, such as
the inpatient cohort of GTWG-HF, likely excluded
patients with less severe or chronic stable HF.
Since cardiovascular trials use inclusion/exclu-
sion criteria to attempt to select patients with
higher cardiovascular risk and lower noncardio-
vascular competing risk, one may expect that
eligible patients have higher cardiovascular out-
come event rates than noneligible, but that for
noncardiovascular outcomes eligible have lower
event rates than noneligible. Therefore, our
observation of greater both cardiovascular, non-
cardiovascular and all-cause mortality in eligible
vs. noneligible patients, suggests that designing
trials to maximize modifiable cardiovascular risk
and minimize nonmodifiable noncardiovascular
risk remains difficult, not only in HFpEF but also
in HFrEF.
Limitations
Eligibility was assessed cross-sectionally and may
change over time reflecting the natural course of
HF. Definitions of some inclusion/exclusion crite-
ria were slightly different from the trials due to the
available variables and EF categories collected in
the SwedeHF registry. As our analysis was based
on a national quality registry with incomplete
coverage (54% in inpatient setting) and patients
enrolled in SwedeHF have been shown to be
younger, have less comorbidities and to receive
better care compared to those who are not in the
registry, generalizability of the results might be
somehow overestimated [19]. Finally, several crite-
ria could not be applied due to lack of required
information in the registry, which might have led to
overestimated eligibility, in particular in the literal
scenario.
Conclusions
In a real-world outpatient HF cohort, 81% of the
patients had EF < 50%, with 63% eligible for
sacubitril/valsartan based on pragmatic criteria
and 29% based on literal trial criteria. Similar
eligibility was observed for EF 40–49% and ≥50%,
suggesting that our eligibility estimates for
EF < 50% may be reproduced whether a higher
cut-off for EF is considered or not. Our data may
help these multiple stakeholders to assess the
implications of recommendations and decisions
and may help future trial design by estimating
consequences of particular inclusion/exclusion
criteria decisions. Ultimately, the use of sacubi-
tril/valsartan may be affected by our study as well
as multiple additional factors, such as interpreta-
tion of the trials, label, guidelines, payor criteria
and comprehensive clinician assessment in indi-
vidual patient cases.
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Additional Supporting Information may be found in
the online version of this article:
Table S1. PARAGON-HF and PARADIGM-HF inclu-
sion/exclusion criteria and corresponding defini-
tions in the Swedish Heart Failure registry.
Table S2. Baseline characteristics according to the
ejection fraction group.
Table S3. Eligibility for sacubitril/valsartan based
on PARADIGM-HF/PARAGON-HF selection criteria
in the main study population (missing data
imputed) by ejection fraction phenotype.
Table S4. Eligibility for sacubitril/valsartan based
on PARADIGM-HF/PARAGON-HF selection criteria
according to the ejection fraction group: consis-
tency analysis.
Table S5. Baseline characteristics in eligible vs.
non eligible patients in the literal scenario.
Table S6. Outcome analysis according to eligibility
status.
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